|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:UCB,_Inc.
|
|
gptkbp:activities
|
S V2 A ligand
|
|
gptkbp:approves
|
gptkb:2016
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Brivaracetam
|
|
gptkbp:category
|
gptkb:unknown
gptkb:C
|
|
gptkbp:clinical_trial
|
Phase III
myoclonic seizures
tonic-clonic seizures
NC T01396128
NC T01402580
NC T01402581
NC T01402582
NC T01402593
partial-onset seizures
|
|
gptkbp:contraindication
|
hypersensitivity to brivaracetam
|
|
gptkbp:dosage_form
|
gptkb:tablet
oral solution
renal impairment
hepatic impairment
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
tablets
oral solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Briviact
|
|
gptkbp:ingredients
|
gptkb:brivaracetam
|
|
gptkbp:interacts_with
|
gptkb:beer
oral contraceptives
other antiepileptic drugs
|
|
gptkbp:is_available_on
|
generic version
|
|
gptkbp:is_used_for
|
treatment of epilepsy
|
|
gptkbp:lifespan
|
approximately 8 to 9 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:UCB_Pharma
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
gptkb:beer
blister pack
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:provides_information_on
|
gptkb:Epilepsy_Foundation
gptkb:American_Academy_of_Neurology
|
|
gptkbp:side_effect
|
gptkb:historical_event
anxiety
dizziness
fatigue
nausea
aggression
irritability
drowsiness
suicidal thoughts
mood changes
|
|
gptkbp:storage
|
room temperature
protected from light
|
|
gptkbp:treatment
|
monotherapy
adjunctive therapy
|